Danaher (DHR) is Gaining from Improvement in Its Bioprocessing Business

Core Insights - Madison Investments reported a 3.43% appreciation for the Madison Large Cap Fund in Q4 2025, outperforming the S&P 500's 2.65% return [1] - The S&P 500 achieved a full-year return of 17.9% for 2025, with a three-year annual growth rate exceeding 21% [1] - Market leadership was characterized by High Beta and Momentum factors, with notable improvements in Healthcare, Financials, and Consumer Discretionary sectors [1] Company Performance - Danaher Corporation (NYSE:DHR) was highlighted as a key contributor to the Madison Large Cap Fund's performance, with a market capitalization of $149.099 billion [2][3] - Danaher reported sales of $24.6 billion in 2025, with a core revenue growth of 2% [3] - The company’s Bioprocessing business is showing improvement, returning to high-single digit growth [3] Hedge Fund Interest - Danaher Corporation ranked 27th among the 30 Most Popular Stocks Among Hedge Funds, with 124 hedge fund portfolios holding its shares at the end of Q4 2025, an increase from 117 in the previous quarter [3]